Harvard Bioscience Stock
Your prediction
Harvard Bioscience Stock
Pros and Cons of Harvard Bioscience in the next few years
Pros
Cons
Performance of Harvard Bioscience vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Harvard Bioscience | 9.800% | -16.393% | 4.615% | -44.490% | -25.818% | -84.308% | -89.149% |
| Simulations Plus | -0.940% | 3.922% | -10.169% | -71.351% | -31.169% | -71.351% | -80.901% |
| Fonar Corp. New | -0.630% | 0.637% | 1.282% | 23.438% | 1.282% | 3.268% | -5.952% |
| MicroVision Inc | 1.490% | -28.992% | -23.071% | -49.498% | -35.434% | -76.406% | -95.993% |
Comments
News
Better Buy: Bitcoin vs. Ethereum
With Bitcoin (CRYPTO: BTC) down 47% from its all-time high of $126,000 just a few months ago, it's perhaps no surprise that crypto investors are starting to look elsewhere for opportunities.
For
Harvard University's Investment Manager Loads Up On 3.87M ETHA Shares
According to a SEC filing dated Feb. 13, 2026, Harvard Management Co. Inc. established a new position in the iShares Ethereum Trust ETF (NASDAQ:ETHA), acquiring 3,870,900 shares. The estimated
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the


